Answers are grounded in this paper and cite their sources.
Objectives: To describe disease management patterns and associated outcomes in patients with type 2 diabetes initiating a second-line glucose-lowering therapy in routine clinical practice in South Africa.Design: Non-interventional observational study.Setting: General and specialist private practices.Subjects Patients with diabetes initiating second-line glucose-lowering therapy.Outcome measures: Variables collected at baseline and at 6-, 12- and 24-month follow-up visits included sociodemographics, first- and second-line glucose-lowering treatments and other medications, reasons for change in diabetes therapy, HbA1c target set by the attending clinician at the time of change, comorbidities and health-related quality of life (HRQoL).Results: Baseline data were collected for 519 patients (69% female). Mean age was 54.6 years and mean time since initial diagnosis was 7.5 years. Mean HbA1c at baseline was 9.0% and the most common second-line treatment approach was to combine metformin with a sulphonylurea. Median HbA1c and median fasting glucose measurements were marginally lower at 24 months than at baseline (8.0% vs. 8.4%, and 8.5 mmol/l vs. 8.8 mmol/l, respectively). Only approximately 5% of patients had had their diabetes medication changed at any time after the baseline visit.Conclusions: Management of type 2 diabetes mellitus in private practice in South Africa is suboptimal.
No takes yet. Share an insight, caveat, or question.
Kok et al. (2021) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: